Хайлтын үр дүнгүүд - Ludger Rose

  • 12-н 1 - 12 үр дүнгүүдийг харуулж байна
Үр дүнг сайжруулах
  1. 1
    Blood lipid concentrations and other cardiovascular risk factors: distribution, prevalence, and detection in Britain

    Blood lipid concentrations and other cardiovascular risk factors: distribution, prevalence, and detection in Britain -н J I Mann, Basil S. Lewis, J. Shepherd, A F Winder, S Fenster, Ludger Rose, B. Morgan

    Хэвлэсэн 1988
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  2. 2
    A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin

    A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or... -н Ildiko Lingvay, Cyrus Desouza, Katarina Lalić, Ludger Rose, Thomas K. Hansen, Jeppe Zacho, Thomas R. Pieber

    Хэвлэсэн 2018
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  3. 3
    Safety and efficacy of insulin degludec/liraglutide (<scp>ID</scp>egLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin‐naïve people with Type 2 diabetes: the <scp>DUAL IV</scp> trial

    Safety and efficacy of insulin degludec/liraglutide (<scp>ID</scp>egLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin‐naïve people with Type 2 diabete... -н Helena W. Rodbard, Bruce W. Bode, Stewart B. Harris, Ludger Rose, Lucine Lehmann, Henrik Jarlov, Jerry Thurman

    Хэвлэсэн 2016
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  4. 4
    Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial

    Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabe... -н Vanita R. Aroda, Stephen C. Bain, Bertrand Cariou, Milivoj Piletič, Ludger Rose, Mads Axelsen, Everton Rowe, J. Hans DeVries

    Хэвлэсэн 2017
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  5. 5
    Efficacy and safety of fast‐acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52‐week, randomized, treat‐to‐target, phase III trial

    Efficacy and safety of fast‐acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52‐week, randomized, treat‐to‐target, phase III trial -н Chantal Mathieu, Bruce W. Bode, Edward Franek, Athena Philis‐Tsimikas, Ludger Rose, Tina Graungaard, Anne Birk Østerskov, David Russell‐Jones

    Хэвлэсэн 2018
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  6. 6
    Fast‐acting insulin aspart versus insulin aspart in the setting of insulin degludec‐treated type 1 diabetes: Efficacy and safety from a randomized double‐blind trial

    Fast‐acting insulin aspart versus insulin aspart in the setting of insulin degludec‐treated type 1 diabetes: Efficacy and safety from a randomized double‐blind trial -н John B. Buse, Anders L. Carlson, Mitsuhisa Komatsu, Ofri Mosenzon, Ludger Rose, Bo Liang, Kristine Buchholtz, Hiroshi Horio, Takashi Kadowaki

    Хэвлэсэн 2018
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  7. 7
    Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial

    Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial -н Helena W. Rodbard, Ildiko Lingvay, John H. Reed, Raymond de la Rosa, Ludger Rose, Danny Sugimoto, Eiichi Araki, Pei-Ling Chu, Nelun Wijayasinghe, Paul Norwood

    Хэвлэсэн 2018
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  8. 8
    Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1)

    Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized,... -н David Russell‐Jones, Bruce W. Bode, Christophe De Block, Edward Franek, Simon Heller, Chantal Mathieu, Athena Philis‐Tsimikas, Ludger Rose, Vincent Woo, Anne Birk Østerskov, Tina Graungaard, Richard M. Bergenstal

    Хэвлэсэн 2017
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  9. 9
    Ladarixin, an inhibitor of the interleukin‐8 receptors <scp>CXCR1</scp> and <scp>CXCR2</scp>, in new‐onset type 1 diabetes: A multicentre, randomized, double‐blind, placebo‐controlled trial

    Ladarixin, an inhibitor of the interleukin‐8 receptors <scp>CXCR1</scp> and <scp>CXCR2</scp>, in new‐onset type 1 diabetes: A multicentre, randomized, double‐blind, placebo‐control... -н Lorenzo Piemonti, Bart Keymeulen, Pieter Gillard, Thomas Linn, Emanuele Bosi, Ludger Rose, Paolo Pozzilli, Francesco Giorgino, Efisio Cossu, L. Daffonchio, Giovanni Goisis, Pier Adelchi Ruffini, Anna Rita Maurizi, Flavio Mantelli, Marcello Allegretti

    Хэвлэсэн 2022
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  10. 10
    Efficacy and safety of cotadutide, a dual glucagon‐like peptide‐1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease

    Efficacy and safety of cotadutide, a dual glucagon‐like peptide‐1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney... -н Victoria Parker, Thuong Hoang, Heike Schlichthaar, Fraser W. Gibb, Barbara Wenzel, Maximillian G. Posch, Ludger Rose, Yi‐Ting Chang, Marcella Petrone, Lars Hansen, Philip Ambery, Lutz Jermutus, Hiddo J.L. Heerspink, Rory J. McCrimmon

    Хэвлэсэн 2022
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  11. 11
    Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial

    Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised cont... -н Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Steven C. Griffen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde, Joseph Proietto, Stephen N Stranks, Roger Chen, David N. O’Neal, Alexia Pape, Mark Forbes, Claire Morbey, Anton Luger, Ursula Hanusch, Christoph Schnack, Evelyn Fliesser-Goerzer, Bertram Hoelzl, Christoph Ebenbichler, Rudolf Prager, Luc Van Gaal, Chris Vercammen, André Scheen, Chantal Mathieu, Francis Duyck, Frank Nobels, Johannes Ruige, Naresh Aggarwal, Vincent Woo, Bruno St-Pierre, R Dumas, Irene Hramiak, Thomas G. Elliott, Troels Krarup Hansen, Jan Erik Henriksen, Jeppe Gram, A. S. Lihn, Jens Meldgaard Bruun, Juha Saltevo, Jyrki Taurio, Jorma Strand, Timo T. Valle, Sakari Nieminen, Kirsi H. Pietiläinen, Bruno Guerci, Samy Hadjadj, Bertrand Cariou, Bruno Vergès, Sophie Borot, A. Penfornis, Thomas Schaum, Diethelm Tschoepe, Cornelia Marck, Thomas Horacek, Ludger Rose, Gerhard Klausmann, Joerg Luedemann, Steffi Appelt, Ulrich Aigner, R Goebel, Thomas Behnke, Anette‐Gabriele Ziegler, Eva Péterfai, Zsuzsanna Kerenyi, Tamás Oroszlán, G Kiss, L. Könyves, Gyorgyi Piros, Moshe Phillip, Ofri Mosenzon, Naim Shehadeh, Faiad Adawi, Julio Wainstein, Francesco Dotta, PierMarco Piatti, Stefano Genovese, Agostino Consoli, Paolo Di Bartolo, Edoardo Mannucci, Carla Giordano, Annunziata Lapolla, Carlos Aguilar, Alberto Esteban, Bazzoni Ruiz, Guillermo Mondragon Ramirez, Emilia Pelayo Orozco, Carlos Alejandro, Stobschinski de Alba, Carlos Medina Pech, Jose Garza Ruiz, Leobardo Sauque Reyna, Guillermo Llamas Esperón, Luis Alejandro Nevarez Ruiz, Maricela Vidrio Velázquez, Fernando Flores Lozano, José Gerardo González‐González, Pedro Alberto García-Hernández

    Хэвлэсэн 2017
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  12. 12
    Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study

    Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study -н Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde, Joseph Proietto, Stephen N Stranks, Roger Chen, David N. O’Neal, Alexia Pape, Mark Forbes, Claire Morbey, Anton Luger, Ursula Hanusch, Christoph Schnack, Evelyn Fliesser-Goerzer, Bertram Hoelzl, Christoph Ebenbichler, Rudolf Prager, Luc Van Gaal, Chris Vercammen, André Scheen, Chantal Mathieu, Francis Duyck, Frank Nobels, Johannes Ruige, Naresh Aggarwal, Vincent Woo, Bruno St-Pierre, R Dumas, Irene Hramiak, Thomas G. Elliott, Troels Krarup Hansen, Jan Erik Henriksen, Jeppe Gram, A. S. Lihn, Jens Meldgaard Bruun, Juha Saltevo, Jyrki Taurio, Jorma Strand, Timo T. Valle, Sakari Nieminen, Kirsi H. Pietiläinen, Bruno Guerci, Samy Hadjadj, Bertrand Cariou, Bruno Vergès, Sophie Borot, A. Penfornis, Diethelm Tschöpe, Thomas Schaum, Cornelia Marck, Thomas Horacek, Ludger Rose, Gerhard Klausmann, Joerg Luedemann, Steffi Appelt, Ulrich Aigner, R Goebel, Thomas Behnke, Anette‐Gabriele Ziegler, Eva Péterfai, Zsuzsanna Kerenyi, Tamás Oroszlán, G Kiss, L. Könyves, Gyorgyi Piros, Moshe Phillip, Ofri Mosenzon, Naim Shehadeh, Faiad Adawi, Julio Wainstein, Francesco Dotta, PierMarco Piatti, Stefano Genovese, Agostino Consoli, Paolo Di Bartolo, Edoardo Mannucci, Carla Giordano, Annunziata Lapolla, Carlos Aguilar, Alberto Esteban Bazzoni Ruiz, Guillermo Mondragon Ramirez, Emilia Pelayo Orozco, Carlos Alejandro Stobschinski de Alba, Carlos Eduardo Medina Pech, Jose Garza Ruiz, Leobardo Sauque Reyna, Guillermo Llamas Esperón, Luis Alejandro Nevarez Ruiz, Maricela Vidrio Velázquez, Fernando Flores Lozano, José Gerardo González‐González, Pedro Alberto García-Hernández, Roberto Araujo Silva, Efraín Villeda-Espinosa, Cristina Mistodie

    Хэвлэсэн 2018
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:

Хайх хэрэгслүүд: